Taysha Gene Therapies Gains Momentum as Wells Fargo Raises Target on Rett Syndrome Program

In a vote of confidence for Taysha Gene Therapies, Inc. (NASDAQ: TSHA), analysts at Wells Fargo have raised the firm's price target on the biotech stock from $8 to $11 while maintaining an Overweight rating. The move, reported earlier this month, reflects growing optimism around the company's lead program for Rett syndrome, a rare and severe neurological disorder.

The optimism stems from concrete regulatory and clinical milestones. Last year, the U.S. Food and Drug Administration (FDA) approved a favorable trial design for Taysha's investigational therapy, TSHA-102. Building on that, the company recently announced it dosed the first patient in the pivotal REVEAL trial phase during the fourth quarter of 2025. Furthermore, the FDA has authorized the use of data from the earlier ASPIRE study to support a future Biologics License Application (BLA).

"The updated target from Wells Fargo signals that institutional investors are starting to price in a higher probability of success for TSHA-102," said market analyst David Chen. "The FDA's engagement on the trial design and data package is a critical, often underrated, step that de-risks the path to market."

Taysha, a clinical-stage company focused on gene therapies for central nervous system diseases, plans to report updated safety and efficacy data from the REVEAL trial in the first half of 2026. The company aims to complete patient dosing across its studies by the second quarter of that year, setting the stage for a potential regulatory submission.

Investor Perspectives:

• Michael Rourke, Portfolio Manager: "This is textbook execution in a high-risk sector. Securing FDA alignment early and hitting clinical milestones on schedule reduces uncertainty. TSHA is transitioning from a purely speculative story to one with definable catalysts."
• Sarah Jennings, Biotech Investor: "Finally, some tangible progress for families waiting for a Rett syndrome treatment. The science has been promising, but clinical translation is everything. This news is a beacon of hope, though the long wait for data continues."
• Dr. Leo Vance, Former Pharma Executive: "Let's not get carried away. A price target hike is an analyst's opinion, not a therapy approval. The gene therapy space is littered with 'promising' programs that failed in Phase 3. The real test is the 2026 data—until then, this is just volatility fuel."
• Priya Mehta, Healthcare Analyst: "The Rett syndrome market represents a significant unmet need. Taysha's AAV-based approach is competitive, but the commercial landscape will depend on efficacy durability and safety profile. These next data readouts will be make-or-break."

The development highlights the sustained interest in targeted gene therapies for monogenic diseases. Success for TSHA-102 could establish a new treatment paradigm for Rett syndrome and validate Taysha's platform for other neurological indications.